Aim: To compare the effectiveness and safety of fixed dose combination of vildagliptin 50mg versus sitagliptin 50mg with metformin 500mg in Type 2 Diabetes Mellitus

 

Method: Retrospective study in 160 subjects divided into two groups, in group A 80 subjects received sitagliptin 50mg with metformin 500mg and 80 subjects in group B received vildagliptin 50mg with metformin 500mg for duration of 24 weeks. Glycated hemoglobin, fasting plasma glucose, postprandial glucose, bodyweight, potassium and creatinine were evaluated as outcomes parameters while safety was evaluated by reporting adverse event including hypoglycemic effect

 

Results: Both groups have shown a greater reduction in plasma glucose parameter: glycated hemoglobin reduced up to 0.97% (P<0.000) for vildagliptin group versus 0.928%(P<0.000) in sitagliptin group, fasting plasma glucose reduced up to 27.46mg/dl (P<0.000) in vildagliptin group versus 20.925mg/dl(P<0.019) for sitagliptin and postprandial glucose reduced up to 42.25mg/dl (P<0.000) for vildagliptin versus 35.260mg/dl(P<0.000) for sitagliptin. There were no significant alteration in kidney parameters in both groups: potassium, creatinine, albumin, body weight was increased by one l kilogram (1.02kg) in sitagliptin group whereas it was reduced by 0.47kg in vildagliptin group. The incidence of hypoglycemic effect were comparable less in both group 6.25% in vildagliptin group versus 5% in sitagliptin group other adverse drug reactions GIT was mild in both group did not require any alteration or discontinuation of the drugs.

 

Conclusion: Both drugs are effective and safe in the management of type 2 diabetes mellitus. These drugs improve plasma glucose and are safe from hypoglycemic effect and they are not associated with the increase of body weight. However, vildagliptin offer a superior benefit over sitagliptin in the management of type 2 diabetes mellitus.